Effectiveness and Safety of Mirikizumab after switching from Ustekinumab in patients with moderate to severe Crohn's disease: results from a long-term extension study

被引：0
|
作者：
D'Haens, G. [1 ]
Laharie, D. [2 ,3 ]
Dulai, P. S. [4 ]
Seibold, F. [5 ]
Siegmund, B. [6 ]
Abraham, B. [7 ,8 ,9 ]
Malter, L. [10 ]
Protic, M. [11 ]
Morris, N. [11 ]
Hozak, R. R. [11 ]
Moses, R. E. [11 ]
Lopes, M. Ugolini [11 ]
Durand, F. [11 ]
Yu, G. [11 ]
Vermeire, S. [12 ]
机构：
[1] Amsterdam Univ Med Ctr, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands
[2] Hop Haut Leveque, CHU Bordeaux, Serv Hepatogastroenterol, Bordeaux, France
[3] Univ Hosp Bordeaux, Digest Oncol Dept, Bordeaux, France
[4] Univ Calif San Diego, Div Gastroenterol, Los Angeles, CA 90089 USA
[5] Crohn Colitis Zentrum Intesto, Lindenhofspital, Bern, Switzerland
[6] Charite, Med Dept, Div Gastroenterol Infectiol & Rheumatol, Berlin, Germany
[7] Houston Methodist Hosp, Houston Methodist Gastroenterol Associates, Houston, TX USA
[8] Houston Methodist Acad Inst, Dept Med, Houston, TX USA
[9] Weill Cornell Med Coll, Dept Med, New York, NY USA
[10] NYU Langone Hlth, Div Gastroenterol, Dept Med, New York, NY USA
[11] Eli Lilly & Co, Lilly Immunol, Indianapolis, IN USA
[12] Univ Hosp Leuven, Dept Gastroenterol & Hepatol, KU Leuven, Dept Chron Dis & Metab, Leuven, Belgium
来源：
JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷
关键词：
D O I：
10.1093/ecco-jcc/jjae190.0085
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP046
引用
收藏
页码：i168 / i170
页数：3
相关论文
共 50 条
  • [31] Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST
    Peyrin-Biroulet, Laurent
    Vermeire, Severine
    D'Haens, Geert
    Panes, Julian
    Dignass, Axel
    Magro, Fernando
    Nazar, Maciej
    Le Bars, Manuela
    Lahaye, Marjolein
    Ni, Lioudmila
    Bravata, Ivana
    Lavie, Frederic
    Daperno, Marco
    Lukas, Milan
    Armuzzi, Alessandro
    Loewenberg, Mark
    Gaya, Daniel R.
    Danese, Silvio
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 (02) : 175 - 185
  • [32] Ustekinumab Maintained Clinically Meaningful Improvement in Health-Related Quality of Life in Patients With Moderate to Severe Crohn's Disease: Results From the IM-UNITI Long-Term Extension
    Sands, Bruce E.
    Han, Chenglong
    Gasink, Christopher
    Bin, Zou
    Stephen, Targan
    Sandborn, William J.
    Feagan, Brian G.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S404 - S404
  • [33] Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease
    Watanabe, Mamoru
    Hibi, Toshifumi
    Mostafa, Nael M.
    Chao, Jingdong
    Arora, Vipin
    Camez, Anne
    Petersson, Joel
    Thakkar, Roopal
    JOURNAL OF CROHNS & COLITIS, 2014, 8 (11): : 1407 - 1416
  • [34] Long-Term Efficacy and Safety of Maintenance Infliximab for the Treatment of Moderate-to-Severe Pediatric Crohn's Disease: Results from the Reach Study
    Hyams, Jeffrey S.
    Blank, Marion
    Johanns, Jewel
    Crandall, Wallace
    Kugathasan, Subra
    Griffiths, Anne M.
    Heuschkel, Robert
    Markowitz, James
    Cohen, Stanley A.
    Winter, Harland S.
    Veereman, Gigi
    Ferry, George D.
    Walters, Thomas D.
    Baldassano, Robert
    GASTROENTEROLOGY, 2009, 136 (05) : A671 - A672
  • [35] EFFICACY AND SAFETY OF USTEKINUMAB IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE IN BRAZIL
    Prra, Rogerio S.
    Chebli, Julio
    Chebli, Liliana
    Bertges, Erika R.
    Ambrogini Junior, Orlando
    Schiavetti, Bianca
    Alves, Antonio, Jr.
    Flores, Cristina
    Lubini, Marcio
    Gasparetti, Newton, Jr.
    Bafutto, Mauro
    Azevedo, Matheus
    Damiao, Aderson O.
    Queiroz, Natalia S.
    Steinwurz, Flavio
    Carvalho, Nayara S.
    Boratto, Sandra D.
    Vilela, Eduardo G.
    Feres, Omar
    Rocha, Jose Joaquim R.
    GASTROENTEROLOGY, 2021, 160 (06) : S414 - S415
  • [36] EFFICACY AND SAFETY UP TO THREE YEARS OF RISANKIZUMAB TREATMENT IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE FORTIFY OPEN-LABEL LONG-TERM EXTENSION
    Ferrante, Marc
    Panaccione, Remo
    Colombel, Jean Frederic
    Dubinsky, Marla C.
    Hisamatsu, Tadakazu
    Lindsay, James O.
    Song, Alexandra P.
    Neimark, Ezequiel
    Zhang, Ying
    Kligys, Kristina
    Crowley, Jameson
    Duan, W. Rachel
    D'Haens, Geert
    GASTROENTEROLOGY, 2024, 166 (05) : S801 - S802
  • [37] Long term efficacy and safety of ustekinumab in patients with moderate to severe psoriasis through 5 years of follow-up: results from the PHOENIX 1 long-term extension
    Papp, K.
    Kimball, A.
    Wasfi, Y.
    Chan, D.
    Bissonnette, R.
    Sofen, H.
    Yeilding, N.
    Li, S.
    Szapary, P.
    Gordon, K.
    JOURNAL OF DERMATOLOGY, 2012, 39 : 239 - 240
  • [38] LONG-TERM CLINICAL EFFECTIVENESS OF USTEKINUMAB IN JAPANESE PATIENTS WITH CROHN'S DISEASE: A RETROSPECTIVE COHORT STUDY
    Ito, Takahiro
    Maemoto, Atsuo
    Katsurada, Takehiko
    Motoya, Satoshi
    Ueno, Nobuhiro
    Fujiya, Mikihiro
    Ashida, Toshifumi
    Hirayama, Daisuke
    Nakase, Hiroshi
    GASTROENTEROLOGY, 2022, 162 (07) : S1099 - S1099
  • [39] Effectiveness, safety and persistence of treatment with ustekinumab in a cohort of patients with moderate-to-severe refractory Crohn's Disease
    Morales Bermudez, A. I.
    Bravo Aranda, A. M.
    Martinez Burgos, M.
    Olmedo Martin, R.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S509 - S510
  • [40] Effectiveness and Safety of Ustekinumab for Moderate to Severely Active Crohn's Disease: Results from an Early Access Program in Brazil
    Chebli, Julio Maria Fonseca
    Parra, Rogerio Serafim
    Flores, Cristina
    Moraes, Antonio Carlos
    Nones, Rodrigo Bremer
    Gomes, Tarcia Nogueira Ferreira
    Perdomo, Ana Maria Bravo
    Scapini, Gustavo
    Zaltman, Cyrla
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (21)
12345